Home Newsfeeds JP Morgan Downgrades Plexus to Underweight

JP Morgan Downgrades Plexus to Underweight

JP Morgan analyst Paul Coster downgrades Plexus (NASDAQ:PLXS) from Neutral to Underweight.

byBenzinga Newsdesk

August 12, 2022

1 minute read

JP Morgan analyst Paul Coster downgrades Plexus (NASDAQ:PLXS) from Neutral to Underweight.

Equinor Inks Long-Term LNG Sale And Purchase Agreement With Cheniere

By Akanksha Bakshi

June 21, 11:25 AM

Cheniere Energy, Inc's (AMEX: LNG) subsidiary, Cheniere Marketing, LLC, has entered into a long-term liquefied natural gas

EQNR

HC Wainwright & Co. Reiterates Buy on Immunocore Hldgs, Maintains $90 Price Target

By Benzinga Newsdesk

March 8, 7:23 AM

HC Wainwright & Co. analyst Patrick Trucchio reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Buy and maintains $90 price target.

IMCR

Jaguar Health Announces FDA Activation Of Third-Party Investigational New Drug Application For Evaluation Of Crofelemer For Treatment Of Uncontrolled Diarrhea In Patient With Short Bowel Syndrome

By Happy Mohamed

August 1, 8:49 AM

Napo Pharmaceuticals, a Jaguar Health company and the manufacturer of crofelemer, is supporting this physician-generated IND SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2023 / Jaguar Health (NASDAQ:JAGX) ("the

JAGX

Eye Disease-Focused Glaukos’ ‘Investor Interest Should Continue To Gain Momentum:’ Analyst

By Vandana Singh

May 2, 3:36 PM

Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive analyst sentiment, driving stock up 6.22%.

GKOS

JP Morgan Downgrades Plexus to Underweight

Related Posts

Equinor Inks Long-Term LNG Sale And Purchase Agreement With Cheniere

HC Wainwright & Co. Reiterates Buy on Immunocore Hldgs, Maintains $90 Price Target

Jaguar Health Announces FDA Activation Of Third-Party Investigational New Drug Application For Evaluation Of Crofelemer For Treatment Of Uncontrolled Diarrhea In Patient With Short Bowel Syndrome

Eye Disease-Focused Glaukos’ ‘Investor Interest Should Continue To Gain Momentum:’ Analyst